Fortitude Family Office’s Pacific Biosciences PACB Stock Holding History

Fortitude Family Office’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9K	Buy	+1,131	New	+$1.64K	﹤0.01%	1499
2026 Q1	–	Sell	-793	Closed	-$1.48K	–	2024
2025 Q4	$1.48K	Hold	793	–	–	﹤0.01%	1297
2025 Q3	$1.01K	Buy	+793	New	+$1.07K	﹤0.01%	1544
2025 Q2	–	Sell	-1,950	Closed	-$2.3K	–	2102
2025 Q1	$2.3K	Hold	1,950	–	–	﹤0.01%	902
2024 Q4	$3.57K	Hold	1,950	–	–	﹤0.01%	922
2024 Q3	$3.31K	Buy	+1,950	New	+$3.2K	﹤0.01%	905

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fortitude Family Office's PACB Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Pacific Biosciences (PACB) in Q2 2026: 1,131 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in PACB as recently as Q4 2025.

Fortitude Family Office first reported a position in PACB in Q3 2024 and has held it in 6 quarters since. The position peaked at $3.57K in Q4 2024. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Fortitude Family Office held 1,131 shares of Pacific Biosciences worth $1.9K as of Q2 2026.
Pacific Biosciences was a new Fortitude Family Office position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1499 holding.
Fortitude Family Office first reported a position in Pacific Biosciences in Q3 2024 and has held it in 6 quarters since.
Fortitude Family Office's Pacific Biosciences position peaked at $3.57K in Q4 2024.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.